Trevi Therapeutics Has Initiated Its Phase 2A RIVER Trial Of Haduvio In Refractory Chronic Cough Patients; Topline Data Is Expected In The Second Half Of 2024
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics has initiated its Phase 2A RIVER trial of Haduvio in refractory chronic cough patients. The topline data from this trial is expected to be released in the second half of 2024.
November 02, 2023 | 11:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Trevi Therapeutics' initiation of the Phase 2A RIVER trial of Haduvio could potentially impact its stock price. However, the topline data from this trial is not expected until the second half of 2024, which may limit any immediate impact.
The initiation of a new trial is generally a positive development for a pharmaceutical company. However, the impact on Trevi Therapeutics' stock price may be limited in the short term as the topline data from the trial is not expected until 2024. The results of the trial will be a more significant driver of the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100